TrueBlue - TBI Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TrueBlue in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TBI shares.
View TBI analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12-month price targets for TrueBlue's shares. Their TBI share price forecasts range from $20.00 to $21.00. On average, they anticipate the company's stock price to reach $20.50 in the next year. This suggests a possible upside of 15.2% from the stock's current price.
View analysts price targets for TBI or view top-rated stocks among Wall Street analysts.

TrueBlue's stock was trading at $19.58 at the start of the year. Since then, TBI stock has decreased by 9.1% and is now trading at $17.80.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, April 24th 2023.
View our TBI earnings forecast.

TrueBlue, Inc. (NYSE:TBI) issued its quarterly earnings data on Wednesday, February, 1st. The business services provider reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.02. The business services provider earned $557.70 million during the quarter, compared to analyst estimates of $562.93 million. TrueBlue had a trailing twelve-month return on equity of 16.95% and a net margin of 2.76%. The business's quarterly revenue was down 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.69 EPS.

ETFs with the largest weight of TrueBlue (NYSE:TBI) stock in their portfolio include First Trust Dow Jones Select Microcap Index Fund (FDM), Invesco S&P SmallCap 600 Pure Value ETF (RZV), Pacer US Small Cap Cash Cows 100 ETF (CALF), Invesco S&P SmallCap Industrials ETF (PSCI), Strategas Global Policy Opportunities ETF (SAGP).Invesco S&P SmallCap 600 Revenue ETF (RWJ) and

TrueBlue updated its first quarter 2023 earnings guidance on Wednesday, February, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $455.00 million-$480.00 million, compared to the consensus revenue estimate of $492.18 million.

34 employees have rated TrueBlue Chief Executive Officer Patrick Beharelle on Glassdoor.com. Patrick Beharelle has an approval rating of 56% among the company's employees. This puts Patrick Beharelle in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other TrueBlue investors own include International Business Machines (IBM), Intel (INTC), NVIDIA (NVDA), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), The Goldman Sachs Group (GS), AT&T (T), Zynga (ZNGA), AbbVie (ABBV) and Amgen (AMGN).

TrueBlue trades on the New York Stock Exchange (NYSE) under the ticker symbol "TBI."

Shares of TBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TBI stock can currently be purchased for approximately $17.80.

TrueBlue (NYSE:TBI) has a market capitalization of $584.25 million and generates $2.25 billion in revenue each year. The business services provider earns $62.27 million in net income (profit) each year or $1.86 on an earnings per share basis.

The company employs 6,500 workers across the globe.

TrueBlue's mailing address is 1015 A STREET, TACOMA WA, 98402. The official website for the company is www.trueblue.com. The business services provider can be reached via phone at (253) 383-9101, via email at investorrelations@trueblueinc.com, or via fax at 877-733-0399.